Biomea Fusion announced the appointment of Juan Pablo Frias, M.D. as CMO. In his new role, Dr. Frias will leverage his deep industry and clinical investigator expertise in the development of therapeutics for the management of diabetes to oversee the clinical development of BMF-219, Biomea’s novel investigational menin inhibitor, for the treatment of type 2 and type 1 diabetes. Steve Morris, M.D., will transition to the new role of Chief Development Officer, where he will continue to lead clinical development of Biomea’s oncology portfolio, including BMF-219, BMF-500 and several early-stage oncology research candidates.Frias has held leadership positions in Clinical and Medical Affairs at Eli Lilly, Amylin Pharmaceuticals, Pfizer, and Johnson & Johnson, where he served as CMO and Global Vice President of Clinical and Medical Affairs, Diabetes Care.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BMEA:
- Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer
- Short Report: Bearish positioning in Beauty Health Company at 2023 lows
- Biomea Fusion reports Q2 EPS (70c), consensus (87c)
- Biomea Fusion Reports Second Quarter 2023 Financial Results and Corporate Highlights
- Largest borrow rate increases among liquid names